Qinlock (Ripretinib) Patent Expiration, LOE Window & CMS Spending

Qinlock (Ripretinib) by Deciphera: FDA Orange Book core substance LOE 2034-05-15 (last listed 2042-10-06), 0 AB generics, $89.2M 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorDeciphera
FDA Application & PathwayN213973 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-05-15
Last Listed Patent or Exclusivity Date2042-10-06
Orange Book Patents (*PED Extensions)42 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$89.2M
2024 Medicare Part D Spend$78.7M
2024 Medicaid Spend$10.6M
Reported Wholesale Price Change (CA SB 17)7 WAC filings (max 25.1% 2-yr change)